Profound Medical (TSE:PRN) Trading Down 26% – Time to Sell?

Profound Medical Corp. (TSE:PRN) shares traded down 26% on Friday . The company traded as low as C$7.30 and last traded at C$7.40. 107,260 shares changed hands during trading, an increase of 504% from the average session volume of 17,746 shares. The stock had previously closed at C$10.00.

Profound Medical Trading Down 28.2%

The company has a debt-to-equity ratio of 14.80, a current ratio of 4.18 and a quick ratio of 14.98. The stock’s 50 day moving average is C$10.18 and its 200-day moving average is C$8.72. The company has a market capitalization of C$260.58 million, a P/E ratio of -5.44 and a beta of 1.10.

Profound Medical (TSE:PRN) last posted its earnings results on Thursday, March 5th. The company reported C$0.37 earnings per share for the quarter. Profound Medical had a negative return on equity of 86.83% and a negative net margin of 287.94%.The firm had revenue of C$8.20 million for the quarter. As a group, equities research analysts anticipate that Profound Medical Corp. will post -1.9000001 earnings per share for the current year.

Insider Transactions at Profound Medical

In other news, insider Thomas Michael Tamberrino acquired 13,908 shares of the firm’s stock in a transaction on Tuesday, December 23rd. The stock was acquired at an average price of C$9.91 per share, for a total transaction of C$137,828.28. Following the completion of the acquisition, the insider owned 39,241 shares in the company, valued at C$388,878.31. This trade represents a 54.90% increase in their ownership of the stock. Company insiders own 8.62% of the company’s stock.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.